MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.174
AS - Asia 5.894
EU - Europa 4.053
SA - Sud America 935
AF - Africa 103
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 5
Totale 21.197
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.005
SG - Singapore 2.059
CN - Cina 1.591
GB - Regno Unito 937
IT - Italia 776
BR - Brasile 718
HK - Hong Kong 706
VN - Vietnam 637
FI - Finlandia 489
SE - Svezia 387
DE - Germania 383
RU - Federazione Russa 245
FR - Francia 216
KR - Corea 195
UA - Ucraina 147
TR - Turchia 135
NL - Olanda 95
BG - Bulgaria 89
AR - Argentina 85
ID - Indonesia 85
IN - India 83
BD - Bangladesh 66
JP - Giappone 63
CA - Canada 59
AT - Austria 56
MX - Messico 55
IQ - Iraq 54
AE - Emirati Arabi Uniti 36
ES - Italia 32
PL - Polonia 32
AU - Australia 30
EC - Ecuador 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 25
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 22
BZ - Belize 20
CO - Colombia 20
BE - Belgio 18
UZ - Uzbekistan 18
PH - Filippine 16
KW - Kuwait 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
PE - Perù 13
CH - Svizzera 12
HU - Ungheria 12
NP - Nepal 12
MY - Malesia 11
SA - Arabia Saudita 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
TH - Thailandia 9
TW - Taiwan 9
AZ - Azerbaigian 8
KE - Kenya 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
UY - Uruguay 7
AL - Albania 6
IL - Israele 6
JO - Giordania 6
RO - Romania 6
TN - Tunisia 6
EE - Estonia 5
EU - Europa 5
GR - Grecia 5
GT - Guatemala 5
LV - Lettonia 5
IR - Iran 4
PR - Porto Rico 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
DK - Danimarca 3
GY - Guiana 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
JM - Giamaica 2
KZ - Kazakistan 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
Totale 21.169
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.483
Singapore 1.251
Fairfield 1.026
Ashburn 983
Hong Kong 697
Hefei 586
Woodbridge 574
Houston 469
Southend 461
San Jose 444
Seattle 440
Chandler 438
Helsinki 433
Wilmington 323
Cambridge 305
London 293
Beijing 263
Ann Arbor 255
Nyköping 235
Ho Chi Minh City 226
Jacksonville 208
The Dalles 204
Dearborn 193
Seoul 191
Modena 178
New York 174
Munich 145
Council Bluffs 142
Hanoi 137
Los Angeles 137
Lauterbourg 113
San Diego 101
Dallas 98
Moscow 98
Chicago 97
Princeton 78
Sofia 78
Milan 72
São Paulo 71
Buffalo 69
Shanghai 63
Jakarta 54
Eugene 51
Salt Lake City 42
Nuremberg 39
Tokyo 38
Bologna 37
Izmir 37
Redondo Beach 37
Amsterdam 36
Rio de Janeiro 35
Columbus 34
Kent 34
Orem 34
Haiphong 30
Frankfurt am Main 29
Redwood City 29
Dublin 27
Boardman 26
Da Nang 24
Elk Grove Village 24
Guangzhou 22
Florence 21
Belize City 20
Mexico City 20
Rome 20
Vienna 20
Atlanta 19
Brooklyn 19
Johannesburg 19
Lappeenranta 19
Reggio Emilia 19
Brasília 18
Toronto 18
Brussels 17
Chennai 17
Baghdad 16
Tashkent 16
Warsaw 16
Ankara 15
Kilburn 15
Portsmouth 15
Denver 14
Kuwait City 14
Montreal 14
Quito 14
Delft 13
Falls Church 13
Paris 13
Phoenix 13
Porto Alegre 13
Tampa 13
Las Vegas 12
Mumbai 12
Norwalk 12
Parma 12
Thái Bình 12
Istanbul 11
Lahore 11
Melbourne 11
Totale 15.137
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 325
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 313
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 300
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 298
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 289
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 274
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 272
Biotherapies in large vessel vasculitis 271
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 271
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 270
Imaging of vasculitis: State of the art 269
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 268
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 265
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 260
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 259
Biologics in vasculitides: Where do we stand, where do we go from now? 255
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 254
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 251
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 248
Increased expression of interleukin-22 in patients with giant cell arteritis 247
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 247
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 237
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 237
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 236
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 233
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 232
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 227
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 224
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 224
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 222
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 220
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 219
Updates on the diagnosis and monitoring of giant cell arteritis 217
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 215
Statin use in giant cell arteritis: a retrospective study 214
Large-vessel giant cell arteritis: a cohort study 211
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 210
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 210
Mycophenolate mofetil in primary central nervous system vasculitis 209
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 209
Tocilizumab for the treatment of giant cell arteritis 208
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 205
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 198
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 194
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 192
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 187
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 187
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 186
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 183
L30. Assessment of vasculitis extent and severity 182
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 182
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 179
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 177
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 176
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 173
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 171
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 170
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 170
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 169
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 167
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 167
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 164
Giant Cell Arteritis and Polymyalgia Rheumatica 160
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 160
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 159
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 159
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 158
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 158
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 156
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 155
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 155
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 151
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 150
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 146
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 145
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 144
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 143
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 143
Development of the Takayasu Arteritis Integrated Disease Activity Index 141
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 138
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 136
What to Know About Biopsy Sampling and Pathology in Vasculitis? 135
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 135
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 135
Eosinophilic giant cell arteritis: A different subset of disease? 135
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 132
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 132
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 132
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 131
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 131
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 131
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 129
Role of miR-146a and miR-146b in Giant Cell Arteritis. 128
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 127
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 127
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 125
IgG4-associated sclerosing mesenteritis 125
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 122
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 122
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 120
Totale 19.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.612
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.612
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021428 0 0 0 0 0 0 0 0 0 168 142 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20267.431 652 414 774 873 960 612 1.203 451 955 537 0 0
Totale 21.414